MCID: ADR005
MIFTS: 58

Adrenal Carcinoma

Categories: Cancer diseases, Endocrine diseases, Neuronal diseases, Rare diseases

Aliases & Classifications for Adrenal Carcinoma

MalaCards integrated aliases for Adrenal Carcinoma:

Name: Adrenal Carcinoma 12 37 15
Adrenal Cancer 12 76 53 55 73
Adrenal Gland Cancer 12 43 15
Adrenal Gland Neoplasms 44 73
Malignant Neoplasm of Adrenal Gland 12
Carcinoma of the Adrenal Gland 12
Neoplasm of the Adrenal Gland 29
Tumor of the Adrenal Gland 12
Neoplasm of Adrenal Gland 12
Adrenocortical Carcinoma 73
Malignant Adrenal Tumor 12
Adrenal Neoplasm 12

Classifications:



External Ids:

Disease Ontology 12 DOID:3950 DOID:3953
ICD10 33 C74 C74.9
ICD9CM 35 194.0
MeSH 44 D000310
NCIt 50 C2859 C9338
SNOMED-CT 68 93665005
KEGG 37 H00033

Summaries for Adrenal Carcinoma

NIH Rare Diseases : 53 Adrenal cancer is a rare form of cancer that occurs due to abnormal and uncontrolled cell growth in the adrenal glands (small glands that sit above each kidney). There are three different types of adrenal cancer which vary by location and the age at which they are often diagnosed:Adrenocortical carcinoma - The most common type of adrenal cancer which develops in the adrenal cortex (the outer part of the adrenal gland) Neuroblastoma - A childhood cancer that begins in the adrenal medulla (the inner part of the adrenal gland) Pheochromocytoma - A neuroendocrine tumor that begins in the adrenal medulla The signs and symptoms associated with the condition largely depend on if the cancer is 'functioning' (producing hormones) or 'nonfunctioning' (not producing hormones) and which hormones are present in excess. In most cases, the underlying cause of the condition is unknown. However, certain genetic conditions such as multiple endocrine neoplasia type 2, Li-Fraumeni syndrome, Von Hippel-Lindau syndrome, neurofibromatosis type I, and Carney complex are associated with an increased risk of developing adrenal tumors and cancer. Treatment may include a combination of surgery, hormone therapy, chemotherapy and radiation therapy.

MalaCards based summary : Adrenal Carcinoma, also known as adrenal cancer, is related to gastrointestinal stromal tumor and hypoaldosteronism, and has symptoms including fever and flank pain. An important gene associated with Adrenal Carcinoma is CRH (Corticotropin Releasing Hormone), and among its related pathways/superpathways are Cytochrome P450 - arranged by substrate type and Aldosterone synthesis and secretion. The drugs Racepinephrine and Epinephrine have been mentioned in the context of this disorder. Affiliated tissues include adrenal gland, kidney and cortex, and related phenotypes are Reduced mammosphere formation and growth/size/body region

Disease Ontology : 12 An endocrine gland cancer located in the adrenal glands which are located above the kidneys.

MedlinePlus : 43 Your adrenal, or suprarenal, glands are located on the top of each kidney. These glands produce hormones that you can't live without, including sex hormones and cortisol, which helps you respond to stress and has many other functions. A number of disorders can affect the adrenal glands, including tumors. Tumors can be either benign or malignant. Benign tumors aren't cancer. Malignant ones are. Most adrenal gland tumors are benign. They usually do not cause symptoms and may not require treatment. Malignant adrenal gland cancers are uncommon. Types of tumors include Adrenocortical carcinoma - cancer in the outer part of the gland Neuroblastoma, a type of childhood cancer Pheochromocytoma - a rare tumor that is usually benign Symptoms depend on the type of cancer you have. Treatments may include surgery, chemotherapy, or radiation therapy.

Wikipedia : 76 An adrenal tumor or adrenal mass is any benign or malignant neoplasms of the adrenal gland, several of... more...

Related Diseases for Adrenal Carcinoma

Diseases related to Adrenal Carcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 175)
# Related Disease Score Top Affiliating Genes
1 gastrointestinal stromal tumor 29.8 ENO2 IGF2 MEN1 SYP
2 hypoaldosteronism 29.5 CYP11B2 POMC REN
3 adenoma 29.4 CYP11B2 CYP21A2 MEN1 POMC
4 pheochromocytoma 29.1 CRH ENO2 MEN1 POMC REN SYP
5 conn's syndrome 28.9 CRH CYP11A1 CYP11B1 CYP11B2 CYP17A1 CYP21A2
6 adrenal adenoma 28.4 CRH CYP11A1 CYP11B1 CYP11B2 CYP17A1 CYP21A2
7 lipoid congenital adrenal hyperplasia 28.0 CYP11A1 CYP11B1 CYP11B2 CYP17A1 CYP21A2 NR5A1
8 adrenocortical carcinoma, hereditary 27.8 CRH CYP11A1 CYP11B1 CYP11B2 CYP17A1 CYP21A2
9 adrenal neuroblastoma 11.1
10 adrenal medulla cancer 11.1
11 multiple endocrine neoplasia, type iib 11.1
12 von hippel-lindau syndrome 11.1
13 adenomatoid tumor 10.4
14 neuroblastoma 10.3
15 hereditary paraganglioma-pheochromocytoma syndromes 10.3
16 sporadic pheochromocytoma 10.3
17 sporadic pheochromocytoma/secreting paraganglioma 10.3
18 adrenocortical carcinoma with pure aldosterone hypersecretion 10.3
19 carotid body cancer 10.3 ENO2 SYP
20 malignant sertoli cell tumor 10.3 ENO2 SYP
21 urinary bladder small cell neuroendocrine carcinoma 10.3 ENO2 SYP
22 auditory system cancer 10.3 ENO2 SYP
23 sinonasal undifferentiated carcinoma 10.3 ENO2 SYP
24 gallbladder small cell carcinoma 10.3 ENO2 SYP
25 cutaneous ganglioneuroma 10.3 ENO2 SYP
26 extrahepatic bile duct adenocarcinoma 10.3 ENO2 SYP
27 small cell carcinoma of the bladder 10.3 ENO2 SYP
28 papillary tumor of the pineal region 10.3 ENO2 SYP
29 sensory organ benign neoplasm 10.3 ENO2 SYP
30 orbital cancer 10.3 ENO2 SYP
31 middle ear adenoma 10.3 ENO2 SYP
32 pulmonary large cell neuroendocrine carcinoma 10.3 ENO2 SYP
33 atypical follicular adenoma 10.3 ENO2 SYP
34 central nervous system primitive neuroectodermal neoplasm 10.3 ENO2 SYP
35 cerebellum cancer 10.3 ENO2 SYP
36 clear cell ependymoma 10.3 ENO2 SYP
37 cauda equina neoplasm 10.3 ENO2 SYP
38 endometrial small cell carcinoma 10.3 ENO2 SYP
39 gastric leiomyosarcoma 10.3 ENO2 IGF2
40 hypothalamic disease 10.3 CRH POMC
41 lymphocytic hypophysitis 10.3 ENO2 POMC
42 extraosseous chondrosarcoma 10.2 ENO2 SYP
43 subependymal glioma 10.2 ENO2 SYP
44 classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency 10.2 CYP21A2 POMC
45 lung oat cell carcinoma 10.2 ENO2 POMC
46 malignant teratoma 10.2 ENO2 SYP
47 pituitary carcinoma 10.2 CRH POMC
48 transsexualism 10.2 CYP17A1 CYP21A2
49 astroblastoma 10.2 ENO2 SYP
50 potter's syndrome 10.2 IGF2 REN

Graphical network of the top 20 diseases related to Adrenal Carcinoma:



Diseases related to Adrenal Carcinoma

Symptoms & Phenotypes for Adrenal Carcinoma

UMLS symptoms related to Adrenal Carcinoma:


fever, flank pain

GenomeRNAi Phenotypes related to Adrenal Carcinoma according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Reduced mammosphere formation GR00396-S 9.17 CYP11B1 CYP21A2 IGF2 LIAS MEN1 POMC

MGI Mouse Phenotypes related to Adrenal Carcinoma:

46 (show all 11)
# Description MGI Source Accession Score Top Affiliating Genes
1 growth/size/body region MP:0005378 10.28 CRH CYP11A1 CYP11B1 CYP11B2 CYP17A1 ENO2
2 behavior/neurological MP:0005386 10.24 CRH CYP11A1 CYP11B1 CYP17A1 ENO2 GRN
3 homeostasis/metabolism MP:0005376 10.21 CRH CYP11A1 CYP11B1 CYP11B2 CYP17A1 GRN
4 cellular MP:0005384 10.16 CRH CYP11A1 CYP11B1 CYP17A1 ENO2 GRN
5 cardiovascular system MP:0005385 10.13 CYP11A1 CYP11B1 CYP11B2 IGF2 LIAS MEN1
6 endocrine/exocrine gland MP:0005379 10.09 CRH CYP11A1 CYP11B1 CYP11B2 IGF2 MEN1
7 mortality/aging MP:0010768 10.03 CYP11A1 CYP11B1 CYP17A1 GRN IGF2 LIAS
8 nervous system MP:0003631 9.93 CRH CYP11A1 CYP11B2 ENO2 GRN IGF2
9 liver/biliary system MP:0005370 9.87 CRH CYP11A1 CYP11B2 GRN IGF2 MEN1
10 renal/urinary system MP:0005367 9.5 CRH CYP11B1 CYP11B2 CYP17A1 IGF2 POMC
11 reproductive system MP:0005389 9.28 CYP11A1 CYP11B2 CYP17A1 GRN IGF2 MEN1

Drugs & Therapeutics for Adrenal Carcinoma

Drugs for Adrenal Carcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 162)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Racepinephrine Approved Phase 3,Phase 2,Phase 1,Not Applicable 329-65-7 838
2
Epinephrine Approved, Vet_approved Phase 3,Phase 2,Phase 1,Not Applicable 51-43-4 5816
3
Mecasermin Approved, Investigational Phase 3 68562-41-4
4
Mitotane Approved Phase 3,Phase 2 53-19-0 4211
5
Doxorubicin Approved, Investigational Phase 3,Phase 2,Phase 1 23214-92-8 31703
6
Streptozocin Approved, Investigational Phase 3 18883-66-4 29327
7
Etoposide Approved Phase 3,Phase 2 33419-42-0 36462
8
Cisplatin Approved Phase 3,Phase 2,Phase 1 15663-27-1 2767 441203 84093
9
Lenograstim Approved, Investigational Phase 3 135968-09-1
10
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
11
Hydrocortisone Approved, Vet_approved Phase 3,Phase 2 50-23-7 5754
12
Hydrocortisone acetate Approved, Vet_approved Phase 3,Phase 2 50-03-3
13
Mifepristone Approved, Investigational Phase 3 84371-65-3 55245
14
Etomidate Approved Phase 3,Phase 1,Phase 2 33125-97-2 667484 36339
15
Isotretinoin Approved Phase 3 4759-48-2 5538 5282379
16
Tretinoin Approved, Investigational, Nutraceutical Phase 3 302-79-4 5538 444795
17
Doxil Approved June 1999 Phase 3,Phase 2,Phase 1 31703
18 Pancreatic Polypeptide Investigational Phase 3,Phase 1 59763-91-6
19 Antineoplastic Agents, Phytogenic Phase 3,Phase 2,Phase 1
20 Cola Phase 3,Phase 2,Phase 1,Early Phase 1
21 Liver Extracts Phase 3,Phase 2,Phase 1,Early Phase 1
22 Peripheral Nervous System Agents Phase 3,Phase 2,Not Applicable
23 Epinephryl borate Phase 3,Phase 2,Phase 1,Not Applicable
24 Antimitotic Agents Phase 3,Phase 2,Phase 1
25 Vasoconstrictor Agents Phase 3,Phase 2,Not Applicable
26 Adrenergic beta-Agonists Phase 3,Phase 2,Not Applicable
27 Anti-Asthmatic Agents Phase 3,Phase 2,Not Applicable
28 Mydriatics Phase 3,Phase 2,Not Applicable
29 Adrenergic alpha-Agonists Phase 3,Phase 2,Not Applicable
30 Autonomic Agents Phase 3,Phase 2,Not Applicable
31 Sympathomimetics Phase 3,Phase 2,Not Applicable
32 Adrenergic Agonists Phase 3,Phase 2,Not Applicable
33 Respiratory System Agents Phase 3,Phase 2,Not Applicable
34 Bronchodilator Agents Phase 3,Phase 2,Not Applicable
35 Adrenergic Agents Phase 3,Phase 2,Not Applicable
36 Neurotransmitter Agents Phase 3,Phase 2,Not Applicable
37 Insulin, Globin Zinc Phase 3,Phase 2
38 insulin Phase 3,Phase 2
39 Mitogens Phase 3,Phase 2
40 Antineoplastic Agents, Hormonal Phase 3,Phase 2
41 Antibiotics, Antitubercular Phase 3,Phase 2,Phase 1
42 Etoposide phosphate Phase 3,Phase 2
43 Anti-Bacterial Agents Phase 3,Phase 2,Phase 1
44 Topoisomerase Inhibitors Phase 3,Phase 2,Phase 1
45 Immunologic Factors Phase 3,Phase 2,Phase 1
46 Adjuvants, Immunologic Phase 3,Phase 2,Phase 1
47 Central Nervous System Depressants Phase 3,Phase 1,Phase 2
48 Adjuvants, Anesthesia Phase 3
49 Anesthetics, Intravenous Phase 3,Phase 1,Phase 2
50 Analgesics, Opioid Phase 3

Interventional clinical trials:

(show top 50) (show all 76)
# Name Status NCT ID Phase Drugs
1 A Study of OSI-906 in Patients With Locally Advanced or Metastatic Adrenocortical Carcinoma Completed NCT00924989 Phase 3 OSI-906
2 Trial in Locally Advanced and Metastatic Adrenocortical Carcinoma Treatment (FIRM-ACT) Completed NCT00094497 Phase 3 Etoposide;Doxorubicin;Cisplatin;Streptozotocin;Mitotane
3 Cisplatin-Based Chemotherapy and/or Surgery in Treating Young Patients With Adrenocortical Tumor Completed NCT00304070 Phase 3 doxorubicin hydrochloride;cisplatin;mitotane;etoposide
4 Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain Completed NCT00538850 Phase 3 Fentanyl sublingual spray;Placebo
5 An Extension Study of CORLUX in the Treatment of Endogenous Cushing's Syndrome Completed NCT00936741 Phase 3 mifepristone
6 A Study of the Efficacy and Safety of CORLUX in the Treatment of Endogenous Cushing's Syndrome Completed NCT00569582 Phase 3 mifepristone
7 Adjuvant Chemotherapy vs. Observation/Mitotane After Primary Surgical Resection of Localized Adrenocortical CarcInoma Recruiting NCT03723941 Phase 3 Cisplatin plus Etoposide
8 Mitotane With or Without Cisplatin and Etoposide After Surgery in Treating Participants With Stage I-III Adrenocortical Cancer With High Risk of Recurrence (ADIUVO-2) Recruiting NCT03583710 Phase 3 Cisplatin;Etoposide;Mitotane
9 Efficacy of Adjuvant Mitotane Treatment (ADIUVO) Recruiting NCT00777244 Phase 3 MITOTANE
10 Combined FDG-PET and 123I-Iodometomidate Imaging for Adrenal Neoplasia Recruiting NCT02010957 Phase 3
11 European Low and Intermediate Risk Neuroblastoma Protocol Recruiting NCT01728155 Phase 3 chemotherapy
12 Sunitinib in Refractory Adrenocortical Carcinoma Unknown status NCT00453895 Phase 2 Sunitinib
13 Sorafenib Plus Paclitaxel in Adreno-Cortical-Cancer Patients Unknown status NCT00786110 Phase 2 Sorafenib;Paclitaxel
14 External-Beam Radiation Therapy With or Without Indinavir and Ritonavir in Treating Patients With Brain Metastases Unknown status NCT00637637 Phase 2 indinavir sulfate;ritonavir
15 Clinical Trial of Dovitinib in First-line Metastatic or Locally Advanced Non-resectable Adrenocortical Carcinoma Completed NCT01514526 Phase 2 Dovitinib
16 Phase II Trial of ZD1839 (Iressa) in Patients With Nonresectable Adrenocortical Carcinoma (ACC) Completed NCT00215202 Phase 2 Iressa (ZD1839)
17 Trial With Taxotere and Cisplatin in Non-operable Adrenocortical Carcinoma Completed NCT00324012 Phase 2 cisplatin, taxotere
18 Phase II Study of Axitinib (AG-013736) With Evaluation of the VEGF-Pathway in Metastatic, Recurrent or Primary Unresectable Adrenocortical Cancer Completed NCT01255137 Phase 2 Axitinib
19 Surgery and Heated Chemotherapy for Adrenocortical Carcinoma Completed NCT01833832 Phase 2 Cisplatin;sodium thiosulfate
20 Gossypol Acetic Acid in Treating Patients With Recurrent, Metastatic, or Primary Adrenocortical Cancer That Cannot Be Removed By Surgery Completed NCT00848016 Phase 2 R-(-)-gossypol acetic acid
21 A Study of Combination Chemotherapy and Surgical Resection in the Treatment of Adrenocortical Carcinoma: Continuous Infusion Doxorubicin, Vincristine and Etoposide With Daily Mitotane Before and After Surgical Resection Completed NCT00001339 Phase 2 doxorubicin, vincristine, and etoposide with mitotane
22 Surgery Plus Chemotherapy (Doxorubicin, Vincristine and Etoposide), Mitotane, and Tariquidar to Treat Adrenocortical Cancer Completed NCT00071058 Phase 2 XR9576 (Tariquidar)
23 A Dose Finding Study of TKM-080301 Infusion in Neuroendocrine Tumors (NET) and Adrenocortical Carcinoma (ACC) Patients Completed NCT01262235 Phase 1, Phase 2 TKM-080301
24 Evaluation of 123I-Iodometomidate for Adrenal Scintigraphy Completed NCT00454103 Phase 1, Phase 2 123I-Iodometomidate
25 Study of Efficacy and Safety of Osilodrostat in Cushing's Syndrome Completed NCT02468193 Phase 2 Osilodrostat
26 A Study of the Safety and Effects of ADH-1 Given Intravenously as a Single Agent Completed NCT00264433 Phase 2 ADH -1 (Exherin™)
27 Combination Chemotherapy and Tamoxifen in Treating Patients With Solid Tumors Completed NCT00002608 Phase 2 cisplatin;doxorubicin hydrochloride;tamoxifen citrate
28 Cixutumumab in Treating Patients With Relapsed or Refractory Solid Tumors Completed NCT00831844 Phase 2
29 Study to Evaluate CORT125134 in Patients With Cushing's Syndrome Completed NCT02804750 Phase 2 CORT125134
30 Oxaliplatin in Treating Young Patients With Recurrent Solid Tumors That Have Not Responded to Previous Treatment Completed NCT00091182 Phase 2 oxaliplatin
31 Cabozantinib in Unresectable/Metastatic Adrenocortical Carcinoma Recruiting NCT03370718 Phase 2 Cabozantinib
32 Cabazitaxel Activity in Patients With Advanced AdrenoCortical-Carcinoma Progressing After Previous Chemotherapy Lines Recruiting NCT03257891 Phase 2 Cabazitaxel
33 Surgery and Heated Intraperitoneal Chemotherapy for Adrenocortical Carcinoma Recruiting NCT03127774 Phase 2 Cisplatin;Sodium thiosulfate
34 Single Agent Pembrolizumab in Subjects With Advanced Adrenocortical Carcinoma Recruiting NCT02673333 Phase 2 Pembrolizumab
35 Nivolumab Combined With Ipilimumab for Patients With Advanced Rare Genitourinary Tumors Recruiting NCT03333616 Phase 2 Ipilimumab;Nivolumab
36 Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wilms Tumor, or Other Rare Tumors Recruiting NCT02867592 Phase 2 Cabozantinib S-malate
37 Nivolumab and Ipilimumab in Treating Patients With Rare Tumors Recruiting NCT02834013 Phase 2
38 Extension Study to Evaluate the Safety and Clinical Benefit of Long-Term Use of Relacorilant in Patients With Cushing Syndrome Recruiting NCT03604198 Phase 2 relacorilant
39 Pembrolizumab in Treating Patients With Rare Tumors That Cannot Be Removed by Surgery or Are Metastatic Recruiting NCT02721732 Phase 2
40 Activity of Abiraterone Acetate in the Management of Cushing's Syndrome in Patients With Adrenocortical Carcinoma Active, not recruiting NCT03145285 Phase 2 Abiraterone Acetate
41 Nivolumab in Treating Patients With Metastatic Adrenocortical Cancer Active, not recruiting NCT02720484 Phase 2 Nivolumab
42 Cabozantinib in Advanced Adrenocortical Carcinoma Not yet recruiting NCT03612232 Phase 2 Cabozantinib-s-malate
43 S9427, Suramin in Treating Patients With Stage III or Stage IV Adrenocortical Cancer Incurable by Surgery Terminated NCT00002921 Phase 2 suramin;therapeutic hydrocortisone
44 IMC-A12 With Mitotane vs Mitotane Alone in Recurrent, Metastatic, or Primary ACC That Cannot Be Removed by Surgery Terminated NCT00778817 Phase 2 mitotane
45 Antineoplaston Therapy in Treating Patients With Stage IV Adrenal Gland Cancer Terminated NCT00003453 Phase 2 Antineoplaston therapy (Atengenal + Astugenal)
46 Treatment Study Using Bevacizumab for Patients With Adrenocortical Carcinoma Withdrawn NCT00469469 Phase 2 Bevacizumab
47 Phase 1 Study of ATR-101 in Subjects With Advanced Adrenocortical Carcinoma Completed NCT01898715 Phase 1 ATR-101
48 Combination Chemotherapy With Suramin Plus Doxorubicin in Treating Patients With Advanced Solid Tumors Completed NCT00003038 Phase 1 doxorubicin hydrochloride;suramin
49 A Pilot Study of Metformin in Patients With a Diagnosis of Li-Fraumeni Syndrome Completed NCT01981525 Phase 1 Metformin
50 Seneca Valley Virus-001 and Cyclophosphamide in Treating Young Patients With Relapsed or Refractory Neuroblastoma, Rhabdomyosarcoma, or Rare Tumors With Neuroendocrine Features Completed NCT01048892 Phase 1 cyclophosphamide

Search NIH Clinical Center for Adrenal Carcinoma

Cochrane evidence based reviews: adrenal gland neoplasms

Genetic Tests for Adrenal Carcinoma

Genetic tests related to Adrenal Carcinoma:

# Genetic test Affiliating Genes
1 Neoplasm of the Adrenal Gland 29

Anatomical Context for Adrenal Carcinoma

MalaCards organs/tissues related to Adrenal Carcinoma:

41
Adrenal Gland, Kidney, Cortex, Adrenal Cortex, Lung, Liver, Bone

The Foundational Model of Anatomy Ontology organs/tissues related to Adrenal Carcinoma:

19
The Adrenal Gl

Publications for Adrenal Carcinoma

Articles related to Adrenal Carcinoma:

(show top 50) (show all 233)
# Title Authors Year
1
Cushing syndrome due to adrenal carcinoma. ( 29633121 )
2018
2
ADRENAL CARCINOMA IN CHILDREN: LONGITUDINAL STUDY IN MINAS GERAIS, BRAZIL. ( 30066822 )
2018
3
Hypertensive choroidopathy and adrenal carcinoma: A new association. ( 30337095 )
2018
4
Pharmacokinetic interaction between mitotane and etoposide in adrenal carcinoma: a pilot study. ( 30533000 )
2018
5
Aggressive adrenal carcinoma in a young patient with Multiple Endocrine Neoplasia 1 syndrome. ( 28625514 )
2017
6
Surgical treatment of adrenal carcinoma. ( 28754418 )
2017
7
Mixed corticomedullary adrenal carcinoma - case report: Comparison in features, treatment and prognosis with the other two reported cases. ( 28199934 )
2017
8
Adrenohepatic fusion: Adhesion or invasion in primary virilizant giant adrenal carcinoma? Implications for surgical resection. Two case report and review of the literature. ( 26684865 )
2016
9
Sarcomatoid Adrenal Carcinoma: Case Report with Contribution to Pathogenesis. ( 27688079 )
2016
10
Evaluation of a large adrenal carcinoma with 3D reconstruction of computed tomography images: A case report and literature review. ( 27567750 )
2016
11
Diagnosis and Management of Hereditary Adrenal Cancer. ( 27075352 )
2016
12
Laparoscopic Adrenalectomy for Adrenal Cancer-A Systematic Review. ( 27215723 )
2016
13
Piecing Together the Adrenal Cancer Puzzle. ( 27246538 )
2016
14
Rare cardiac involvement in adrenal carcinoma. ( 26301653 )
2015
15
RRM1 modulates mitotane activity in adrenal cancer cells interfering with its metabolization. ( 25497672 )
2015
16
A Rare Presentation of Primary Hyperparathyroidism with Concurrent Aldosterone-Producing Adrenal Carcinoma. ( 26161274 )
2015
17
Pathology in practice. Mediastinal thyroid follicular carcinoma and adrenal carcinoma. ( 25587729 )
2015
18
Exploiting the Unusual to Find the Rare: Novel Steroid Metabolites Pinpoint Adrenal Cancer Patients. ( 26069029 )
2015
19
Functional ectopic adrenal carcinoma in a dog. ( 25183891 )
2014
20
Incidental renal cell carcinoma originating from a native kidney after en-bloc resection for adrenal carcinoma in a kidney transplant recipient. ( 24656033 )
2014
21
Histoplasmosis mimicking adrenal carcinoma. ( 24600775 )
2014
22
Senile primary aldosteronism associated with adrenal carcinoma. ( 24796641 )
2014
23
Adrenal cancer in 2013: Time to individualize treatment for adrenocortical cancer? ( 24393782 )
2014
24
Management of adrenal cancer: a 2013 update. ( 24458831 )
2014
25
Adrenal cancer in neurofibromatosis type 1: case report and DNA analysis. ( 25520849 )
2014
26
Adrenal carcinoma: a retrospective analysis of our series. ( 23540614 )
2013
27
Pregnancy in a patient with adrenal carcinoma treated with mitotane: a case report and review of literature. ( 23275528 )
2013
28
A case of androgen-secreting adrenal carcinoma with non-classical congenital adrenal hyperplasia. ( 24251173 )
2013
29
Neoadjuvant chemotherapy and salvage surgery for an aldosterone-producing adrenal carcinoma with inferior vena cava thrombus: case report and literature review. ( 23810165 )
2013
30
Mixed corticomedullary adrenal carcinoma. ( 23435808 )
2013
31
A giant adrenal pseudocyst mimicking an adrenal cancer: case report and review of the literature. ( 23548497 )
2013
32
Successful pulmonary thrombectomy for malignant tumor thrombus after adrenal cancer resection. ( 24080241 )
2013
33
Giant adrenal carcinoma associated with renal vein and inferior vena cava thrombus. Case report and literature review. ( 22732784 )
2012
34
The role of radiation therapy in the management of adrenal carcinoma and adrenal metastases. ( 22488095 )
2012
35
Feminizing adrenal carcinoma presenting with heart failure and ventricular tachycardia. ( 22937299 )
2012
36
Analysis of energy utilization and body composition in kidney, bladder, and adrenal cancer patients. ( 20884257 )
2012
37
Adrenal cancer: scientific advances. ( 22108436 )
2012
38
Systemic therapy for advanced adrenal cancer. ( 22488742 )
2012
39
Management of adjuvant mitotane therapy following resection of adrenal cancer. ( 22706605 )
2012
40
Structural requirements for mitotane activity: development of analogs for treatment of adrenal cancer. ( 22753730 )
2012
41
The ENSAT registry: a digital repository supporting adrenal cancer research. ( 22797043 )
2012
42
Adrenal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. ( 22997446 )
2012
43
KIAA0101 is overexpressed, and promotes growth and invasion in adrenal cancer. ( 22096502 )
2011
44
Effect of combined lignan phytoestrogen and melatonin treatment on secretion of steroid hormones by adrenal carcinoma cells. ( 21529220 )
2011
45
Normal delivery following resection of an androgen-secreting adrenal carcinoma. ( 29699081 )
2011
46
Triptolide induces apoptosis in human adrenal cancer NCI-H295 cells through a mitochondrial-dependent pathway. ( 21152873 )
2011
47
Chemotherapy for advanced adrenal cancer: improvement from a molecular approach? ( 21883840 )
2011
48
Adrenal cancer: clinical advances. ( 22173667 )
2011
49
Constitutive beta-catenin activation induces adrenal hyperplasia and promotes adrenal cancer development. ( 20106872 )
2010
50
Primary hepatocellular carcinoma in ectopic liver masquerading as left adrenal carcinoma: a rare occurrence. ( 21139837 )
2010

Variations for Adrenal Carcinoma

Cosmic variations for Adrenal Carcinoma:

9 (show top 50) (show all 65)
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA GRCh38 Location Conf
1 COSM17666 VHL adrenal gland,adrenal gland,pheochromocytoma,malignant c.593T>C p.L198P 3:10149916-10149916 29
2 COSM14311 VHL adrenal gland,adrenal gland,pheochromocytoma,malignant c.499C>T p.R167W 3:10149822-10149822 29
3 COSM5885100 VHL adrenal gland,adrenal gland,pheochromocytoma,malignant c.250G>A p.V84M 3:10142097-10142097 29
4 COSM329087 NF1 adrenal gland,adrenal gland,pheochromocytoma,malignant c.4558C>T p.Q1520* 17:31260496-31260496 29
5 COSM24441 NF1 adrenal gland,adrenal gland,pheochromocytoma,malignant c.3721C>T p.R1241* 17:31235623-31235623 29
6 COSM14283 VHL adrenal gland,adrenal gland,pheochromocytoma,benign c.491A>G p.Q164R 3:10149814-10149814 27
7 COSM17662 VHL adrenal gland,adrenal gland,pheochromocytoma,benign c.492G>T p.Q164H 3:10149815-10149815 27
8 COSM18097 VHL adrenal gland,adrenal gland,pheochromocytoma,benign c.482G>A p.R161Q 3:10149805-10149805 27
9 COSM14321 VHL adrenal gland,adrenal gland,pheochromocytoma,benign c.227T>A p.F76Y 3:10142074-10142074 27
10 COSM6444479 VHL adrenal gland,adrenal gland,pheochromocytoma,benign c.260T>C p.V87A 3:10142107-10142107 27
11 COSM144975 VHL adrenal gland,adrenal gland,pheochromocytoma,benign c.475A>G p.K159E 3:10149798-10149798 27
12 COSM100047 VHL adrenal gland,adrenal gland,pheochromocytoma,benign c.389T>G p.V130G 3:10146562-10146562 27
13 COSM17982 VHL adrenal gland,adrenal gland,pheochromocytoma,benign c.496G>T p.V166F 3:10149819-10149819 27
14 COSM236660 VHL adrenal gland,adrenal gland,pheochromocytoma,benign c.250G>C p.V84L 3:10142097-10142097 27
15 COSM966 RET adrenal gland,adrenal gland,pheochromocytoma,benign c.1900T>C p.C634R 10:43114500-43114500 27
16 COSM965 RET adrenal gland,adrenal gland,pheochromocytoma,benign c.2753T>C p.M918T 10:43121968-43121968 27
17 COSM220089 NF1 adrenal gland,adrenal gland,pheochromocytoma,benign c.1885G>A p.Q616fs*4 17:31225134-31225134 27
18 COSM329092 NF1 adrenal gland,adrenal gland,pheochromocytoma,benign c.1721+3A>T p.A548fs*13 17:31221932-31221932 27
19 COSM30670 NF1 adrenal gland,adrenal gland,pheochromocytoma,benign c.7646C>G p.S2549* 17:31356490-31356490 27
20 COSM329090 NF1 adrenal gland,adrenal gland,pheochromocytoma,benign c.226G>T p.E76* 17:31159031-31159031 27
21 COSM5885098 NF1 adrenal gland,adrenal gland,pheochromocytoma,benign c.5665G>T p.E1889* 17:31330351-31330351 27
22 COSM329093 NF1 adrenal gland,adrenal gland,pheochromocytoma,benign c.1722-1G>A p.? 17:31223443-31223443 27
23 COSM329089 NF1 adrenal gland,adrenal gland,pheochromocytoma,benign c.1466A>G p.Y489C 17:31214524-31214524 27
24 COSM327926 NF1 adrenal gland,adrenal gland,pheochromocytoma,benign c.3158C>A p.S1053* 17:31230886-31230886 27
25 COSM327927 NF1 adrenal gland,adrenal gland,pheochromocytoma,benign c.7582C>T p.Q2528* 17:31352381-31352381 27
26 COSM33676 NF1 adrenal gland,adrenal gland,pheochromocytoma,benign c.6855C>A p.Y2285* 17:31338739-31338739 27
27 COSM1710108 NF1 adrenal gland,adrenal gland,pheochromocytoma,benign c.7300C>T p.Q2434* 17:31349230-31349230 27
28 COSM330588 NF1 adrenal gland,adrenal gland,pheochromocytoma,benign c.2409+1G>A p.A776_Q803del 17:31227607-31227607 27
29 COSM330587 NF1 adrenal gland,adrenal gland,pheochromocytoma,benign c.205-1G>C p.R69fs*7 17:31159009-31159009 27
30 COSM5946188 MET adrenal gland,adrenal gland,pheochromocytoma,benign c.352A>T p.M118L 7:116699436-116699436 27
31 COSM707 MET adrenal gland,adrenal gland,pheochromocytoma,benign c.3029C>T p.T1010I 7:116771936-116771936 27
32 COSM5967149 MET adrenal gland,adrenal gland,pheochromocytoma,benign c.607T>A p.S203T 7:116699691-116699691 27
33 COSM496 HRAS adrenal gland,adrenal gland,pheochromocytoma,benign c.181C>A p.Q61K 11:533875-533875 27
34 COSM499 HRAS adrenal gland,adrenal gland,pheochromocytoma,benign c.182A>G p.Q61R 11:533874-533874 27
35 COSM486 HRAS adrenal gland,adrenal gland,pheochromocytoma,benign c.37G>C p.G13R 11:534286-534286 27
36 COSM1732355 H3F3A adrenal gland,adrenal gland,pheochromocytoma,benign c.103G>T p.G35W 1:226064454-226064454 27
37 COSM19176 FGFR1 adrenal gland,adrenal gland,pheochromocytoma,benign c.1638C>A p.N546K 8:38417331-38417331 27
38 COSM6188660 EPAS1 adrenal gland,adrenal gland,pheochromocytoma,benign c.1592C>T p.P531L 2:46380264-46380264 27
39 COSM6196778 EPAS1 adrenal gland,adrenal gland,pheochromocytoma,benign c.1104G>A p.M368I 2:46376608-46376608 27
40 COSM6196613 EPAS1 adrenal gland,adrenal gland,pheochromocytoma,benign c.1589C>A p.A530E 2:46380261-46380261 27
41 COSM6188649 EPAS1 adrenal gland,adrenal gland,pheochromocytoma,benign c.1595A>G p.Y532C 2:46380267-46380267 27
42 COSM45444 TP53 adrenal gland,adrenal gland,adrenal cortical adenoma,cortisol producing c.587G>T p.R196L 17:7674944-7674944 22
43 COSM43555 TP53 adrenal gland,adrenal gland,adrenal cortical adenoma,cortisol producing c.736A>G p.M246V 17:7674227-7674227 22
44 COSM225014 RB1 adrenal gland,adrenal gland,adrenal cortical adenoma,cortisol producing c.1960G>A p.V654M 13:48456349-48456349 22
45 COSM4167506 PRKACA adrenal gland,adrenal gland,adrenal cortical adenoma,cortisol producing c.617T>G p.L206R 19:14097604-14097604 22
46 COSM27887 GNAS adrenal gland,adrenal gland,adrenal cortical neoplasm,cortisol producing c.601C>T p.R201C 20:58909365-58909365 22
47 COSM27899 GNAS adrenal gland,adrenal gland,adrenal cortical adenoma,cortisol producing c.601C>A p.R201S 20:58909365-58909365 22
48 COSM27895 GNAS adrenal gland,adrenal gland,adrenal cortical adenoma,cortisol producing c.602G>A p.R201H 20:58909366-58909366 22
49 COSM4962873 GNAS adrenal gland,adrenal gland,adrenal cortical adenoma,cortisol producing c.679C>G p.Q227E 20:58909540-58909540 22
50 COSM5663 CTNNB1 adrenal gland,adrenal gland,adrenal cortical adenoma,cortisol producing c.133T>C p.S45P 3:41224645-41224645 22

Expression for Adrenal Carcinoma

Search GEO for disease gene expression data for Adrenal Carcinoma.

Pathways for Adrenal Carcinoma

Pathways related to Adrenal Carcinoma according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.94 CYP11A1 CYP11B1 CYP11B2 CYP17A1 CYP21A2 POMC
2
Show member pathways
12.53 CYP11A1 CYP11B1 CYP11B2 CYP17A1 CYP21A2 NR5A1
3 12.27 CYP11A1 CYP17A1 ENO2 STAR
4
Show member pathways
11.68 CRH CYP11A1 CYP11B1 CYP17A1 CYP21A2 MEN1
5 11.6 CRH CYP11A1 CYP11B1 CYP21A2 POMC STAR
6
Show member pathways
11.54 CYP11A1 CYP11B1 CYP11B2 CYP17A1 CYP21A2
7
Show member pathways
11.44 CYP11A1 CYP11B1 CYP11B2 CYP17A1 CYP21A2 POMC
8 11.27 CYP11A1 CYP17A1 STAR
9
Show member pathways
10.99 CYP11B1 CYP11B2 CYP17A1 CYP21A2
10 10.28 CRH POMC

GO Terms for Adrenal Carcinoma

Biological processes related to Adrenal Carcinoma according to GeneCards Suite gene sharing:

(show all 19)
# Name GO ID Score Top Affiliating Genes
1 response to drug GO:0042493 9.86 CCNB1 CRH REN STAR
2 steroid metabolic process GO:0008202 9.8 CRH CYP11A1 CYP11B1 CYP11B2 CYP17A1 CYP21A2
3 male gonad development GO:0008584 9.72 NR5A1 REN STAR
4 cholesterol metabolic process GO:0008203 9.71 CYP11A1 CYP11B1 CYP11B2 STAR
5 regulation of blood pressure GO:0008217 9.69 CYP11B1 POMC REN
6 cellular response to peptide hormone stimulus GO:0071375 9.67 CYP11A1 CYP11B1 CYP11B2 MEN1
7 adrenal gland development GO:0030325 9.58 CRH NR5A1
8 regulation of neuronal synaptic plasticity GO:0048168 9.58 STAR SYP
9 response to corticosterone GO:0051412 9.57 CRH STAR
10 C21-steroid hormone biosynthetic process GO:0006700 9.56 CYP11A1 CYP11B1 CYP11B2 STAR
11 sterol metabolic process GO:0016125 9.55 CYP11A1 CYP11B1 CYP11B2 CYP17A1 CYP21A2
12 cellular response to potassium ion GO:0035865 9.54 CYP11B1 CYP11B2
13 regulation of steroid biosynthetic process GO:0050810 9.52 NR5A1 STAR
14 diterpenoid metabolic process GO:0016101 9.49 CRH STAR
15 mineralocorticoid biosynthetic process GO:0006705 9.48 CYP11B2 CYP21A2
16 aldosterone biosynthetic process GO:0032342 9.46 CYP11B1 CYP11B2
17 cortisol biosynthetic process GO:0034651 9.43 CYP11B1 CYP11B2
18 steroid biosynthetic process GO:0006694 9.43 CYP11A1 CYP11B1 CYP11B2 CYP17A1 CYP21A2 STAR
19 glucocorticoid biosynthetic process GO:0006704 9.1 CRH CYP11A1 CYP11B1 CYP11B2 CYP17A1 CYP21A2

Molecular functions related to Adrenal Carcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 oxidoreductase activity GO:0016491 9.77 CYP11A1 CYP11B1 CYP11B2 CYP17A1 CYP21A2
2 hormone activity GO:0005179 9.58 CRH IGF2 POMC
3 heme binding GO:0020037 9.55 CYP11A1 CYP11B1 CYP11B2 CYP17A1 CYP21A2
4 insulin-like growth factor receptor binding GO:0005159 9.43 IGF2 REN
5 iron ion binding GO:0005506 9.35 CYP11A1 CYP11B1 CYP11B2 CYP17A1 CYP21A2
6 corticosterone 18-monooxygenase activity GO:0047783 9.32 CYP11B1 CYP11B2
7 steroid 11-beta-monooxygenase activity GO:0004507 9.26 CYP11B1 CYP11B2
8 oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen GO:0016705 9.02 CYP11A1 CYP11B1 CYP11B2 CYP17A1 CYP21A2

Sources for Adrenal Carcinoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....